| |
Univariate analysis
|
Multivariate analysis
|
|---|
|
Assessment
|
HR (95% CI)
|
P-value
|
HR (95% CI)
|
P-value
|
|---|
|
Δ0 to 3 m BASDAI
|
0.672 (0.579 to 0.780)
|
0.000
| |
*
|
|
Δ0 to 3 m ASDASCRP
|
0.434 (0.327 to 0.577)
|
0.000
|
0.488 (0.317 to 0.752)
|
0.001
|
|
Δ0 to 3 m physician's GDA
|
0.643 (0.543 to 0.772)
|
0.000
|
0.739 (0.600 to 0.909)
|
0.004
|
|
Δ0 to 3 m patient's GDA
|
0.735 (0.641 to 0.844)
|
0.000
| |
*
|
|
Δ0 to 3 m CRP
|
0.977 (0.954 to 1.002)
|
0.068
| |
*
|
|
Δ0 to 3 m ESR
|
0.975 (0.950 to 1.001)
|
0.064
| |
*
|
|
Δ0 to 3 m BALP Z-score
|
1.291 (0.969 to 1.720)
|
0.081
| |
*
|
|
Δ0 to 3 m PINP Z-score
|
1.014 (0.688 to 1.493)
|
0.944
| |
**
|
|
Δ0 to 3 m sCTX Z-score
|
0.513 (0.367 to 0.717)
|
0.000
|
0.394 (0.263 to 0.591)
|
0.000
|
- Data of 105 AS patients were analyzed: 72 patients who continued versus 33 patients who discontinued their first TNF-α blocking agent because of inefficacy and/or adverse events.
- Δ0 to 3 m, change from baseline to three months. See Table 1 for other abbreviations.
- HR refers to the risk of anti-TNF-α treatment discontinuation per 1 grade or 1 point.
- * The variable was not selected during multivariate Cox regression analysis (P ≥ 0.05).
- ** The variable was not tested in multivariate Cox regression analysis because of a P-value > 0.3 in univariate analysis.
